We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Clinical-Grade Recombinant Proteins for Cell Therapy

Clinical-Grade Recombinant Proteins for Cell Therapy content piece image
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AMSBIO announces the launch of its StemFit Purotein® range of high purity, high activity recombinant proteins for cell therapy applications.


Continued expansion of cell therapy applications across healthcare and the life sciences is driving a rapidly increasing need for clinically applicable ancillary materials. A key requirement is for recombinant proteins, such as growth factors and cytokines. This demand for clinically applicable recombinant proteins places stringent requirements on product quality, lot-to-lot consistency, and compliance with all relevant laws and regulations.


All StemFit Purotein® products are designed and manufactured under a strict animal-free protocol** which minimizes risk of virus contamination and ensures high lot-to-lot consistency. Manufactured using a streamlined (optionally GMP compliant) production and purification process results in recombinant proteins of the highest purity and quality while maintaining affordable prices. The StemFit Purotein® range includes recombinant proteins that play key roles in differentiation of ES and iPS cells into liver, pancreas, kidney, heart, blood, and immune cells. Beneficially, StemFit Purotein® products are supplied in a ‘ready-to-use’ frozen liquid form which eliminates the time-consuming process of reconstitution while ensuring consistent results.


Purotein® products are fully compatible with the StemFit® range of xeno-free, chemically defined media which is proven to effectively maintain induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) under feeder-free conditions during the reprogramming, expansion and differentiation phases of stem cell culture and growth medium.